ConcertAI, a frontrunner in oncology-focused generative and agentic AI SaaS, has announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines into its advanced platforms. This integration will empower both research and clinical oncology communities through enhanced decision support and patient outcome optimization.
Developments and Integrations
1. Integration with CARAai and Precision Suite
- ASCO Guidelines are now accessible through CARAai for Precision Suite and CancerLinQ® SmartLinQ™ users.
- Researchers can assess guideline-concordant care in real-time and track outcomes over time.
- Data-driven insights enable more informed decisions across the biopharma research pipeline.
2. Enhanced Clinical Support for CancerLinQ Network
- SmartLinQ now delivers ASCO guideline-based recommendations for individual patient cases.
- Enhances oncologists’ ability to evaluate treatment options comprehensively.
- Recommendations are integrated into other SmartLinQ features for a holistic treatment view.
3. Strategic Partnership and Historical Context
- In December 2023, ConcertAI acquired CancerLinQ from ASCO, consolidating operations under its umbrella.
- Over the past 18 months, SmartLinQ has been enhanced for QOPI® applications and diagnostic/therapeutic alerts.
- Seamlessly integrates with electronic medical records (EMRs) like Epic, improving usability within existing clinical workflows.
4. Timeline and Accessibility
- ASCO Guidelines will be incorporated into SmartLinQ by June 15th, 2025.
- Precision Suite users will gain access to guideline features by June 30th, 2025.
- A demo will be available at the 2025 ASCO Annual Meeting in Chicago.
5. Broader Implications for Clinical Trials
- Supports design and optimization of clinical trials based on established ASCO recommendations.
- Facilitates more robust trial controls and better alignment with evidence-based oncology practices.
The integration of ASCO Guidelines into ConcertAI’s oncology platforms marks a significant leap in combining clinical excellence with AI innovation. With enhanced decision support for oncologists and greater analytical capabilities for researchers, this collaboration sets a new benchmark in the pursuit of precision cancer care.
